Mass spectrometry strategies to power drug discovery
In this first master class session, explore how advanced mass spectrometry strategies are powering the next generation of drug discovery through chemoproteomics. A Thermo Fisher Scientific leader will examine quantitative approaches tailored to modern screening workflows, including proteins of interest, thermal proteome profiling, and targeted protein degradation.
Through instrument-specific datasets and real-world case studies, you’ll see how chemoproteomics enables confident target identification and accelerates discovery pipelines. Gain practical insights into deploying DIA, TMT, and PRM strategies—and learn how to scale mass spectrometry workflows to meet the evolving demands of drug discovery programs.
Why Attend
- Discover how advanced mass spectrometry strategies are accelerating target identification and drug discovery through chemoproteomics
- Learn from a Thermo Fisher Scientific leader through real-world datasets and applied case studies
- Understand how DIA, TMT, and PRM approaches support diverse chemoproteomic screening strategies
- Explore how scalable MS workflows can be implemented across early discovery and translational research programs
Presenter: Brett Larsen (Sr. Marketing Specialist Proteomics, Thermo Fisher Scientific)
Brett Larsen is a leader in chemoproteomics and post-translational modification analysis at Thermo Fisher Scientific. With over 25 years of mass spectrometry experience, he has led proteomics at LTRI Toronto and advanced applications at MDS Proteomics. Brett brings practical expertise in translating complex workflows into real-world discovery.
